Integrated QSAR, docking, pharmacokinetics, and molecular dynamics approaches for designing IRAK4 inhibitors against MYD88^L265P-driven diffuse large B-cell lymphoma
Abstract Interleukin-1 receptor-associated kinase 4 (IRAK4) is a key mediator of MYD88^L265P-driven diffuse large B-cell lymphoma (DLBCL) and a promising drug target. We applied an integrated in silico pipeline, namely, 2D-QSAR (MLR with GA), molecular docking, ADMET profiling, and 100-ns molecular...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer
2025-12-01
|
| Collection: | Discover Chemistry |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1007/s44371-025-00391-w |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|